Patient Support Helpline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

For Seventh Consecutive Year, ZERO Named a Top Nonprofit to Work For

Media Contact:

Ilana Ostrin




Alexandria, Va., April 2, 2020 – For the seventh consecutive year, ZERO Prostate Cancer has been named one of the Top 50 Best Nonprofits to Work For” by The Nonprofit Times. ZERO was ranked number 12, making it the seventh time the organization has landed in the top 50.

As the nation’s leading nonprofit in the fight against prostate cancer, ZERO advances research, improves the lives of men and families, and inspires action. With the dedication and energy of more than two dozen staff nationwide, thousands of prostate cancer patients and families benefit from ZERO’s critical support resources, programs, and services. ZERO is the top-ranked health nonprofit on this year’s list. 

“All the credit of this wonderful honor goes to our culture and my colleagues. Our culture of high responsibility and high freedom enables us to build trust, resolve conflict, and drive toward commitment and results quicker than most organizations. It also empowers all team members to achieve work-life balance,” said ZERO CEO and President Jamie Bearse. “Now more than ever during the COVID-19 crisis, it’s incredibly important to have a high performing culture where we’re all highly aligned but working remotely. I’m tremendously grateful to have an amazingly thoughtful, compassionate, and dedicated team to help our at-risk community during this heightened time of need.”

“ZERO is in the business of changing lives, for both patients and employees,” said Senior Director of Operations, Josh Craddock. “It’s evident that year after year, ZERO’s leadership has invested in its culture and made it a top priority. When a talented team can all rally around together what is most important, you feel empowered to truly make a difference. There is nothing better than hearing from a prostate cancer patient that we’ve helped.”

ZERO’s team members are collaborative, flexible, and ready to tackle any challenge in order to make an impact. Passionate, hard-working, talented, and bright are just a few of the qualities of the organization’s outstanding team. It is ZERO’s high-freedom and high-responsibility culture paired with a passionate team that truly fosters the ideal environment for collaboration, growth, and positive results for patients and their families. ZERO is rated four out of four stars on Charity Navigator, the largest and most-utilized evaluator of charities in the United States.

To view this year’s list, click here.

To learn more about ZERO’s culture and available internships at ZERO, click here


About ZERO Prostate Cancer
ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. From early detection to survivorship, ZERO is the premier resource for prostate cancer patients and their families to access comprehensive support, make meaningful connections, and take action to save lives. Our dedicated national and chapter staff is joined with a growing team of passionate volunteer champions to increase advocacy, awareness, and community engagement to ZERO out prostate cancer. ZERO is recognized with four out of four stars by Charity Navigator and accredited by the Better Business Bureau. ZERO spends more on programs than any other prostate cancer charity, dedicating 85 cents of every dollar to support, education, and research.